Alnylam Director Charles Elliott Sigal Receives Stock Awards and Options

This Form 4 filing reports that Charles Elliott Sigal, a director of Alnylam Pharmaceuticals, received equity awards on May 20, 2026. Sigal acquired 671 shares of common stock through restricted stock units (RSUs) that vest upon the earlier of the first anniversary of the grant date or his retirement/resignation, provided such departure occurs no more than 90 days before the first anniversary. He also received 1,441 stock options with an exercise price of $298.48 per share, expiring May 20, 2036, with similar vesting terms. Following these transactions, Sigal directly holds 1,446 shares and indirectly holds 2,000 shares through a family trust. The awards were granted under Alnylam's Second Amended and Restated 2018 Stock Incentive Plan as part of director compensation.